Large Language Model Assistance for Clinical Decision-Making Among Rural Physicians
Effect of Large Language Model Assistance on Clinical Decision-Making Among Rural Physicians: A Randomized Controlled Trial
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Rural physicians play an essential role in the diagnosis and management of common and frequently occurring conditions, referral decision-making, chronic disease management, and patient education. In resource-constrained primary care settings, they often face limited access to medical information and specialist support, delays in updating clinical knowledge and guidelines, and substantial pressure in clinical decision-making. These challenges are particularly relevant in northwestern China, where primary care resources are relatively limited. Improving rural physicians' abilities in diagnostic assessment, recognition of clinical warning signs, and rational prescribing is therefore an important priority for strengthening primary healthcare services.
Large language models (LLMs) can support medical information retrieval, organization of diagnostic and management approaches, differential diagnosis, medication-related decision-making, patient education, and follow-up planning, and may therefore serve as accessible tools for supporting clinical decision-making in primary care. However, general-purpose LLMs were not specifically developed for use in resource-constrained primary care settings and have not been adequately evaluated among rural physicians. Their responses may contain factual errors or fabricated evidence, overlook warning signs, provide insufficient medication safety warnings, or recommend investigations and treatments that are not feasible in local primary care settings. Without adequate verification skills, physicians may fail to benefit from LLM assistance and may even introduce new safety risks. It is therefore important to evaluate how rural physicians use LLMs and whether structured training can improve the safe and effective use of these tools before their wider implementation.
This randomized controlled trial will evaluate the effects of LLM assistance and brief training on clinical decision-making among rural physicians. Participants will complete clinical cases involving common conditions encountered in primary care, with tasks assessing diagnostic judgment, recognition of warning signs, rational treatment, and patient education. Some participants will also use the LLM as a second-opinion tool to review and revise their initial decisions. All responses will be independently evaluated by reviewers blinded to group assignment using standardized scoring criteria to assess overall clinical decision-making performance and safety.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Liyuan Tao, MD
- Numéro de téléphone: +86 82265732
- E-mail: tendytly@163.com
Lieux d'étude
-
-
Xinjiang Uygur Autonomous Region
-
Karamay, Xinjiang Uygur Autonomous Region, Chine
- Xinjiang Second Medical College
-
Contact:
- Zejiang Ma, Master of Medicine
- Numéro de téléphone: +86 18811331959
- E-mail: 18811331959@163.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Currently engaged in clinical practice at a rural primary healthcare institution in northwestern China.
- Has received formal medical education and holds a relevant diploma or degree.
- Able to read and understand clinical case materials in Chinese.
- Able to use a computer to complete the study tasks.
- Willing to participate and able to provide written informed consent.
Exclusion Criteria:
- Previously involved in the development of the clinical case tasks, reference answers, or scoring rubric for this study.
- Previously participated in pilot testing involving the same clinical case tasks or study procedures.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: Randomisé
- Modèle interventionnel: Affectation factorielle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Conventional Resources Followed by LLM Second Opinion
Participants receive no LLM-use training.
During the initial 60-minute assessment, they complete the clinical cases using conventional non-LLM resources only.
After submitting their initial responses, they receive an additional 30 minutes to use the study-provided LLM as a second-opinion tool to review and revise their responses.
|
During the initial 60-minute assessment, participants complete primary care clinical cases using conventional non-LLM resources only, including clinical guidelines, textbooks, drug labels, training materials, medical websites, and standard search engines.
Participants are not permitted to use LLMs during this phase.
After completing and submitting their initial responses using conventional non-LLM resources, participants receive an additional 30 minutes to use the study-provided DeepSeek-V4 as a second-opinion tool.
They may review, verify, and revise their initial clinical decisions before submitting their final responses.
|
|
Expérimental: Direct LLM Assistance
Participants receive no LLM-use training and may use the study-provided LLM throughout the initial 60-minute assessment to complete the clinical cases.
They submit their final responses at 60 minutes and do not participate in the additional second-opinion phase.
|
During the initial 60-minute assessment, participants may use the study-provided DeepSeek-V4 to assist with medical information retrieval, diagnostic and management reasoning, identification of warning signs, referral decisions, rational prescribing, patient education, and follow-up planning.
Participants remain responsible for their final clinical decisions and responses.
|
|
Expérimental: LLM Training and Conventional Resources Followed by LLM Second Opinion
Participants receive brief structured training on the safe and effective use of LLMs.
During the initial 60-minute assessment, they complete the clinical cases using conventional non-LLM resources only.
After submitting their initial responses, they receive an additional 30 minutes to use the study-provided LLM as a second-opinion tool to review and revise their responses.
|
During the initial 60-minute assessment, participants complete primary care clinical cases using conventional non-LLM resources only, including clinical guidelines, textbooks, drug labels, training materials, medical websites, and standard search engines.
Participants are not permitted to use LLMs during this phase.
After completing and submitting their initial responses using conventional non-LLM resources, participants receive an additional 30 minutes to use the study-provided DeepSeek-V4 as a second-opinion tool.
They may review, verify, and revise their initial clinical decisions before submitting their final responses.
Before completing the clinical cases, participants receive brief structured training on the safe and effective use of LLMs.
The training covers the role and limitations of LLMs, structured prompting and follow-up questioning, identification of warning signs and referral indications, medication safety, verification of LLM-generated information, high-risk situations in which LLMs should not be relied upon, and protection of patient privacy.
|
|
Expérimental: LLM Training and Direct LLM Assistance
Participants receive brief structured training on the safe and effective use of LLMs and may use the study-provided LLM throughout the initial 60-minute assessment to complete the clinical cases.
They submit their final responses at 60 minutes and do not participate in the additional second-opinion phase.
|
During the initial 60-minute assessment, participants may use the study-provided DeepSeek-V4 to assist with medical information retrieval, diagnostic and management reasoning, identification of warning signs, referral decisions, rational prescribing, patient education, and follow-up planning.
Participants remain responsible for their final clinical decisions and responses.
Before completing the clinical cases, participants receive brief structured training on the safe and effective use of LLMs.
The training covers the role and limitations of LLMs, structured prompting and follow-up questioning, identification of warning signs and referral indications, medication safety, verification of LLM-generated information, high-risk situations in which LLMs should not be relied upon, and protection of patient privacy.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall Clinical Decision-Making Score
Délai: At the end of the initial 60-minute assessment
|
Participants' responses to primary care clinical cases will be evaluated using a prespecified scoring rubric.
The overall score will reflect performance across key components of clinical decision-making.
Higher scores indicate better overall clinical decision-making performance.
|
At the end of the initial 60-minute assessment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Diagnostic Judgment Domain Score
Délai: At the end of the initial 60-minute assessment
|
Participants' diagnostic judgment in response to primary care clinical cases will be evaluated using a predefined scoring rubric.
Higher scores indicate better diagnostic judgment.
|
At the end of the initial 60-minute assessment
|
|
Clinical Warning Sign Recognition Domain Score
Délai: At the end of the initial 60-minute assessment
|
Participants' ability to identify clinically important warning signs in primary care clinical cases will be evaluated using a predefined scoring rubric.
Higher scores indicate better recognition of clinical warning signs.
|
At the end of the initial 60-minute assessment
|
|
Treatment Plan Domain Score
Délai: At the end of the initial 60-minute assessment
|
Participants' proposed treatment plans for primary care clinical cases will be evaluated using a predefined scoring rubric.
Higher scores indicate better treatment planning performance.
|
At the end of the initial 60-minute assessment
|
|
Change in Overall Clinical Decision-Making Score After LLM Review
Délai: Change from 60 to 90 minutes after the start of the assessment
|
Among participants assigned to the LLM second-opinion phase, the change in overall clinical decision-making score will be calculated as the score after LLM-assisted review minus the score before LLM-assisted review.
Positive values indicate improvement in overall clinical decision-making performance.
|
Change from 60 to 90 minutes after the start of the assessment
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- IRB00006761-M20260614
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .